Estrogen plus progestin increased risk for stroke and probable dementia in postmenopausal women

November 2003
ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p62
Academic Journal
This article cites a study regarding whether hormone replacement therapy (HRT) increases the risk of stroke in postmenopausal women. The incidence of ischemic and hemorrhagic strokes combined and of ischemic stroke alone were greater in the HRT group than in the placebo group. The groups did not differ for incidence of hemorrhagic stroke. The results were also not influenced by previous HRT use or timing of previous HRT initiation with respect to the final menstrual period.


Related Articles

  • Estrogen plus progestin increased risk for stroke and probable dementia in postmenopausal women: COMMENTARY. Atkins, David // ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p63 

    Most observational studies have reported substantially lower risk for dementia among women who had used hormone replacement therapy (HRT). The expectations of a protective effect against dementia were based on a compelling combination of basic science and epidemiology. In animal studies,...

  • HRT increases risk of dementia and stroke.  // Contemporary OB/GYN;Jul2003, Vol. 48 Issue 7, p16 

    Reports on studies of the effect of postmenopausal hormone therapy (HRT) on the risk of dementia and stroke. Incidence of dementia in women taking estrogen plus progestin; Cognitive function of women receiving the estrogen/progestin treatment; Percentage increase in the risk of stroke among...

  • Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.  // Current Medical Literature: Stroke Review;2003, Vol. 7 Issue 3, p85 

    Reports on additional analyses from the Women's Health Initiative (WHI) trial of estrogen plus progestin on stroke in postmenopausal women. Goal of assessing the effect of estrogen plus progestin on ischemic and hemorrhagic stroke; Indication that conjugated equine estrogen plus...

  • HRT: WHI results strike another blow.  // PharmaWatch: Cancer;April 2003, Vol. 2 Issue 4, p20 

    Reports on the analysis of data from the Women's Health Initiative study showing that women using estrogen-progestin hormone replacement therapy (HRT) experienced more strokes. Presentation of the results at the International Stroke Conference of the American Heart Association; Assessment of the...

  • Hormone replacement therapy preparations. Sturdee, David W. // Journal of the British Menopause Society;2000, Vol. 6 Issue 1, p34 

    The article reports on licensed hormone replacement therapy regimens in Great Britain. The most suitable initial treatment for 80 percent of women is oral estrogen. About 15 percent of women have transdermal estrogen. For over 50 years, pellets of crystallized estradiol have been available for...

  • Progestin found vital in hormone replacement therapy. Dickinson, Ben // Drug Topics;3/4/96, Vol. 140 Issue 5, p64 

    Highlights the findings of a study concerning the use of conjugated equine estrogen (CEE) for hormone replacement therapy in postmenopausal women. Endometriums of women who enrolled in a postmenopausal estrogen-progestin interventions trial; Effects of estrogen with or without a progestin on...

  • Postmenopausal Hormone Use and Secondary Prevention of Coronary Events in the Nurses' Health Study. Grodstein, Francine; Manon, JoAnn E.; Stampfer, Meir J. // Annals of Internal Medicine;7/3/2001, Vol. 135 Issue 1, p1 

    Discusses results of a study on the effectiveness of postmenopausal hormone use in the secondary prevention of coronary events. Patient characteristics; Decreasing recurrence of major coronary heart disease events with increasing duration of hormone use; Absence of difference between users of...

  • Hormone trial for disease prevention stopped early. Tanne, Janice Hopkins // BMJ: British Medical Journal (International Edition);7/13/2002, Vol. 325 Issue 7355, p61 

    Reports that the Women's Health Initiative stopped a U.S. clinical trial to evaluate estrogen and progestogen in postmenopausal women. Purpose of the study to examine whether estrogen plus progestogen has a favourable or unfavourable effect on coronary heart disease and overall risks and...

  • Raloxifene Versus Continuous Combined Estrogen/Progestin Therapy: Densitometric and Biochemical Effects in Healthy Postmenopausal Taiwanese Women. Tsai, K. S.; Yen, M. L.; Pan, H. A.; Wu, M. H.; Cheng, W. C.; Hsu, S. H. J.; Yen, B. L.; Huang, K. E. // Osteoporosis International;Dec2001, Vol. 12 Issue 12, p1020 

    : We treated 116 healthy postmenopausal women (age 47–66 years, mean 57 years) in Taiwan with either raloxifene (RLX) 60 mg (n= 92) or 0.625 mg conjugated equine estrogen plus 5 mg medroxyprogesterone acetate (CCEP, n= 24) daily for 12 months in a randomized, double-masked,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics